Join us at AAHFN 2022 | Abbott
CARDIOVASCULAR
hamburger
Life-changing Technology at the Heart of Care

Visit us at AAHFN 2022 in Booth 301. You can learn more about how we put patients’ needs at the heart of everything we do and meet with our patient ambassadors who are living life with the CardioMEMS™ HF System.

Join us at an industry symposium that will highlight how presymptomatic data from CardioMEMS HF System can help more patients earlier in their heart failure journeys.

Industry Symposium

Right Patient, Right Intervention, Right Time
The Value of Presymptomatic Data

Thursday, June 16, 2022 | 6:45pm - 8:15pm ET
Gaitlin A4

Heart failure is a complex clinical syndrome that can be challenging to manage. In this program, we will discuss how pulmonary artery pressure monitoring can provide heart failure care teams with the clarity to optimize medical therapy, prevent heart failure hospitalizations and know when a patient may be ready for advanced therapies. We will discuss how new clinical data have supported this technology being approved for even more patients. Care teams will now have access to valuable presymptomatic data to slow the progression of heart failure sooner for their patients.
 

Presenters:

Lisa Rathman, MSN, CRNP, CHFN, CCRN
Lead Nurse Practitioner for the Heart Failure Program
Penn Medicine Lancaster General Health
Christopher Chien, M.D., FACC
Assistant Professor of Medicine
Medical Director, REX Heart Failure Clinic
UNC Health


This Symposium is not part of the AAHFN official educational program and the sessions and content are not endorsed by AAHFNI. This Symposium is a promotional activity and is not approved for continuing education credit. The content and opinions expressed by presenters are those of the company, sponsor or presenter and not the AAHFN.

CardioMEMS™ HF System Now Approved to Help More Patients

Now you can help slow the progression of heart failure, since the expanded indication allows us to bring the benefits of the CardioMEMS HF System to healthier NYHA Class II and III patients who have had an elevated BNP, with or without a recent heart failure hospitalization. That means you don't have to wait for a patient to have a heart failure hospitalization before being able to customize their treatment plan and prevent further decompensation.

Earlier Intervention with Presymptomatic Data

Monitoring pulmonary artery (PA) pressure daily, the CardioMEMS HF System gives you unique presymptomatic data that you do not get from any other remote hemodynamic monitor. This important data is an early indicator of worsening heart failure and can inform proactive treatment adjustments up to thirty days before weight gain, or other heart failure symptoms appear.²

Preserves Patient Lifestyles

Manage Patients Remotely

Remote management means a decrease in frequency of visits and commuting to appointments, so patients enjoy more of their day-to-day activities.

Remote Monitoring

Improve Quality of Life

Presymptomatic data allows you to provide personalized, trend-based heart failure management. This proactive care can make patients feel re-energized and may help prevent them from being readmitted to the hospital.

Improve Quality of Life

25,000+ Patients Implanted

Now that it’s approved for more patients, the CardioMEMS HF System should be considered for all your heart failure patients, who are actively being treated to prevent heart failure progression and hospitalizations. With the CardioMEMS HF System, you’ll have access to your patient’s data in real time so they can worry less about their heart failure and get back to focusing on life.

25,000+ Patients Implanted

Connect With Us

We would love to connect with you at AAHFN 2022! Stop by booth 301 to meet with an Abbott representative or fill out the form below. We’ll follow up with you soon.

 

 

References

  1. Lindenfeld J, Zile MR, Desai AS, et al. Hemodynamic-guided management of heart failure (GUIDE-HF): a randomized controlled trial. Lancet 2021;398:991-1001.
  2. Adamson, et al. Pulmonary artery pressure-guided heart failure management reduces 30-day readmissions. Circulation: Heart Failure. 2016;115.002600.

 

INDICATIONS, SAFETY AND WARNINGS

Rx Only

Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.

CardioMEMS™ HF System Indications and Usage: The CardioMEMS HF System is indicated for wirelessly measuring and monitoring pulmonary artery pressure and heart rate in NYHA Class II or III heart failure patients who either have been hospitalized for heart failure in the previous year and/or have elevated natriuretic peptides. The hemodynamic data are used by physicians for heart failure management with the goal of controlling pulmonary artery pressures and reducing heart failure hospitalizations.

CardioMEMS™ HF System Contraindications: The CardioMEMS™ HF System is contraindicated for patients with an inability to take dual antiplatelet or anticoagulants for one month post implant.

CardioMEMS™ HF System Potential Adverse Events: Potential adverse events associated with the implantation procedure include, but are not limited to, the following: air embolism, allergic reaction, infection, delayed wound healing, arrhythmias, bleeding, hemoptysis, hematoma, nausea, cerebrovascular accident, thrombus, cardiovascular injury, myocardial infarction, death, embolization, thermal burn, cardiac perforation, pneumothorax, thoracic duct injury and hemothorax.

MAT-2206038 v2.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.